XTL Biopharmaceuticals Ltd. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating income was USD 303,000 compared to operating loss of USD 217,000 a year ago. Net loss was USD 1.150 million compared to USD 1.105 million a year ago. Basic loss per share from continuing operations was USD 0.002 compared to USD 0.002 a year ago. For the half year, operating loss was USD 535,000 compared to operating Income of USD 474,000 a year ago. Net loss was USD 865,000 compared to USD 932,000 a year ago. Basic loss per share from continuing operations was USD 0.002 compared to USD 0.002 a year ago.